0000950170-22-021603 Sample Contracts

Amendment No. 3 to the Exclusive Research, Development Option and License Agreement dated March 1, 2018, as amended by Amendments dated July 4, 2019 and October 30, 2019 (the “Agreement”)

Magenta Therapeutics, Inc. • November 3rd, 2022 • Pharmaceutical preparations • New York

• Company
  Magenta Therapeutics, Inc.
• Filed
  November 3rd, 2022
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

WHEREAS, Magenta and HDPR wish to amend certain provisions of the Agreement that relate to each Party’s rights to use certain intellectual property rights;